OBJECTIVE: Green fluorescent protein (GFP) has been used to monitor and select cells transduced with vectors encoding other transgenes of interest. We investigated the immunogenic nature of GFP in humans and further explored whether this xenoprotein could be used as a functional adjuvant to enhance T-cell immunity to the melanoma tumor antigen MART1. METHODS: Peripheral blood lymphocytes from healthy donors were stimulated by autologous dendritic cells expressing GFP, then cloned by limiting dilution and tested for antigen specificity following coculture with GFP-expressing or GFP-negative targets. In a parallel experiment, lymphocytes from HLA A 0201+ healthy donors were stimulated with four different Melan-A/MART1(27-35) peptide-pulsed stimulators: 1) MART1 peptide-pulsed DCs, 2) MART1 peptide-pulsed DCs loaded with GFP protein, 3) MART1 peptide-pulsed GFP adenovirus-transduced DCs, and 4) MART1 peptide-pulsed null adenovirus-transduced DCs. The percentage of CD3+/CD8+ MART1 peptide-specific T cells was determined by intracellular cytokine staining for gamma-IFN. RESULTS: Multiple CD4+ and CD8+ T cell clones were expanded which secreted gamma-IFN and demonstrated high levels of cytotoxicity to GFP-expressing targets as assessed by ELISA and Cr51 release respectively. We next investigated the impact of GFP expression on DCs used to stimulate cytotoxic T cells specific for a tumor-associated peptide. The percentage of MART1- specific CD8+ T cells that were generated was higher when MART1-pulsed GFP adenovirus-transduced DCs were used as stimulators (28%) compared to MART1-pulsed DCs alone (11%, p = 0.01), MART1-pulsed null adenovirus-transduced DCs (11.7%, p = 0.02), or MART1-pulsed DCs loaded with GFP protein (12.2%). CONCLUSIONS: These findings further support GFP's immunogenicity and suggest this xenoprotein might further be used to enhance the expansion of tumor-specific T cells.
OBJECTIVE: Green fluorescent protein (GFP) has been used to monitor and select cells transduced with vectors encoding other transgenes of interest. We investigated the immunogenic nature of GFP in humans and further explored whether this xenoprotein could be used as a functional adjuvant to enhance T-cell immunity to the melanoma tumor antigen MART1. METHODS: Peripheral blood lymphocytes from healthy donors were stimulated by autologous dendritic cells expressing GFP, then cloned by limiting dilution and tested for antigen specificity following coculture with GFP-expressing or GFP-negative targets. In a parallel experiment, lymphocytes from HLA A 0201+ healthy donors were stimulated with four different Melan-A/MART1(27-35) peptide-pulsed stimulators: 1) MART1 peptide-pulsed DCs, 2) MART1 peptide-pulsed DCs loaded with GFP protein, 3) MART1 peptide-pulsed GFP adenovirus-transduced DCs, and 4) MART1 peptide-pulsed null adenovirus-transduced DCs. The percentage of CD3+/CD8+ MART1 peptide-specific T cells was determined by intracellular cytokine staining for gamma-IFN. RESULTS: Multiple CD4+ and CD8+ T cell clones were expanded which secreted gamma-IFN and demonstrated high levels of cytotoxicity to GFP-expressing targets as assessed by ELISA and Cr51 release respectively. We next investigated the impact of GFP expression on DCs used to stimulate cytotoxic T cells specific for a tumor-associated peptide. The percentage of MART1- specific CD8+ T cells that were generated was higher when MART1-pulsed GFP adenovirus-transduced DCs were used as stimulators (28%) compared to MART1-pulsed DCs alone (11%, p = 0.01), MART1-pulsed null adenovirus-transduced DCs (11.7%, p = 0.02), or MART1-pulsed DCs loaded with GFP protein (12.2%). CONCLUSIONS: These findings further support GFP's immunogenicity and suggest this xenoprotein might further be used to enhance the expansion of tumor-specific T cells.
Authors: J Pleticha; S A Malkmus; L F Heilmann; S L Veesart; R Rezek; Q Xu; T L Yaksh; A S Beutler Journal: Gene Ther Date: 2014-10-30 Impact factor: 5.250
Authors: Laëtitia Le Texier; Katie E Lineburg; Benjamin Cao; Cameron McDonald-Hyman; Lucie Leveque-El Mouttie; Jemma Nicholls; Michelle Melino; Blessy C Nalkurthi; Kylie A Alexander; Bianca Teal; Stephen J Blake; Fernando Souza-Fonseca-Guimaraes; Christian R Engwerda; Rachel D Kuns; Steven W Lane; Michele Teng; Charis Teh; Daniel Gray; Andrew D Clouston; Susan K Nilsson; Bruce R Blazar; Geoffrey R Hill; Kelli Pa MacDonald Journal: JCI Insight Date: 2016-09-22
Authors: Piotr Hadaczek; John Forsayeth; Hanna Mirek; Keith Munson; John Bringas; Phil Pivirotto; Jodi L McBride; Beverly L Davidson; Krystof S Bankiewicz Journal: Hum Gene Ther Date: 2009-03 Impact factor: 5.695
Authors: Hong Song; Karineh Shahverdi; David L Huso; Yuchuan Wang; James J Fox; Robert F Hobbs; Barjor Gimi; Kathleen L Gabrielson; Martin G Pomper; Benjamin M Tsui; Zaver Bhujwalla; R Todd Reilly; George Sgouros Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Lei Huang; Ramireddy Bommireddy; Luis E Munoz; Rohini N Guin; Changyong Wei; Amanda Ruggieri; Ashwathi P Menon; Xiaoxian Li; Mala Shanmugam; Taofeek K Owonikoko; Suresh S Ramalingam; Periasamy Selvaraj Journal: PLoS One Date: 2021-08-19 Impact factor: 3.240
Authors: Stijn De Munter; Alexander Van Parys; Layla Bral; Joline Ingels; Glenn Goetgeluk; Sarah Bonte; Melissa Pille; Lore Billiet; Karin Weening; Annick Verhee; Jose Van der Heyden; Tom Taghon; Georges Leclercq; Tessa Kerre; Jan Tavernier; Bart Vandekerckhove Journal: Int J Mol Sci Date: 2020-01-30 Impact factor: 5.923
Authors: Astrid Strack; Andrea Deinzer; Christian Thirion; Silke Schrödel; Jan Dörrie; Tatjana Sauerer; Alexander Steinkasserer; Ilka Knippertz Journal: Viruses Date: 2022-01-05 Impact factor: 5.048